ScripPRISM BioLab got away a successful initial public offering on 2 July on the Tokyo Stock Exchange's Growth Market for venture firms, raising close to $12m for the drug discovery-focused Japanese bioven
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Coya And Dr Reddy’s Ink Deal For C
Pink SheetAmong the most notable new drugs in Japan's latest listing of reimbursement prices are Novo Nordisk A/S ’s blockbuster obesity therapy Wegovy (semaglutide), Chugai Pharmaceutical Co., Ltd. / Roche H
ScripVenture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments